摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-nitro-phenyl)-crotonic acid ethyl ester | 80854-57-5

中文名称
——
中文别名
——
英文名称
3-(4-nitro-phenyl)-crotonic acid ethyl ester
英文别名
3-(4-Nitro-phenyl)-crotonsaeure-aethylester;ethyl 3-(4-nitrophenyl)but-2-enoate;p-Nitro-β-methyl-zimtsaeure-aethylester;Ethyl 3-(4-nitrophenyl)-2-butenoate
3-(4-nitro-phenyl)-crotonic acid ethyl ester化学式
CAS
80854-57-5
化学式
C12H13NO4
mdl
MFCD25970302
分子量
235.24
InChiKey
GXKAVJLXZLKIAJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    329.5±11.0 °C(Predicted)
  • 密度:
    1.184±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    72.1
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:b0c78ad2cc4d6572fb6c11dbbaccc86c
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(4-nitro-phenyl)-crotonic acid ethyl esterpotassium carbonate 作用下, 以 甲醇 为溶剂, 反应 4.0h, 以82 mg的产率得到β-methyl-4-nitrocinnamic acid
    参考文献:
    名称:
    Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition
    摘要:
    从已知的可逆抑制剂CP4d开始,我们设计了两类新的抑制剂,提高了两者的效力(22b)和对谷胱甘肽的抵抗力(27d)。
    DOI:
    10.1039/c6md00565a
  • 作为产物:
    参考文献:
    名称:
    Schroeter; Wuelfing, Chemische Berichte, 1907, vol. 40, p. 1594
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Simple Preparation of 4-Aryl- and 4-Alkyl-2(5<i>H</i>)-furanones from β-Substituted Crotonic Esters
    作者:Shinzo Kagabu、Yasuhiro Shimizu、Chinatsu Ito、Koichi Moriya
    DOI:10.1055/s-1992-26237
    日期:——
    Treatment of ß-aryl- or ß-alkylcrotonic esters with selenium dioxide in acetic acid in the presence of a catalytic amount of perchloric acid gave 4-substituted 2(5H)-furanones in moderate to good yields.
    用二氧化硒处理β-芳基或β-烷基克罗烯酸酯,在醋酸中加入催化量的高氯酸,得到了4-取代的2(5H)-呋喃酮,产率中等到良好。
  • (Carboxy-oxo-pyrrolidino)phenylalkenamides and esters thereof as SRS-A
    申请人:Pfizer Inc.
    公开号:US04296120A1
    公开(公告)日:1981-10-20
    Certain new propenamide and 2-butenamide compounds, having a (4-carboxy-2-oxo-pyrrolidino)phenyl substituent at the 3-position, and certain esters thereof, and their use for antagonizing the spasmogenic activity of slow-reacting substance of anaphylaxis (SRS-A) in a human subject. In particular, the compounds of the invention are useful for preventing and treating certain obstructive airways diseases, notably allergic bronchial asthma, allergic rhinitis and certain skin disorders, in human subjects.
    某些新的丙烯酰胺和2-丁烯酰胺化合物,在3位具有(4-羧基-2-氧代吡咯烷基)苯基取代基,以及某些酯类化合物,用于拮抗人体内缓激肽反应物(SRS-A)的痉挛原性活性。特别地,本发明的化合物对于预防和治疗某些阻塞性呼吸道疾病,特别是过敏性支气管哮喘、过敏性鼻炎和某些皮肤疾病,在人体内有用。
  • (Carboxyacylamino)phenylalkenamides and esters thereof as SRS-A
    申请人:Pfizer, Inc.
    公开号:US04296129A1
    公开(公告)日:1981-10-20
    Certain new propenamides and 2-butenamides having a (carboxyalkanamido)phenyl or a (carboxyalkenamido)phenyl group at the 3-position, and certain esters thereof, and their use for antagonizing the spasmogenic activity of slow-reacting substance of anaphylaxis (SRS-A) in a human subject. In particular, the compounds of the invention are useful for preventing and treating certain obstructive airways diseases, notably allergic bronchial asthma, allergic rhinitis and certain skin disorders, in human subjects.
    本发明涉及某些在3位具有(羧基烷酰胺)苯基或(羧基烯酰胺)苯基基团的新型丙烯酰胺和2-丁烯酰胺,以及某些酯类,以及它们用于拮抗人体内缓激物质(SRS-A)的痉挛原性活动和预防和治疗某些阻塞性呼吸道疾病,尤其是过敏性支气管哮喘,过敏性鼻炎和某些皮肤疾病,适用于人体主体。
  • Carboxamide compounds as SRS-A antagonists
    申请人:Pfizer Inc.
    公开号:US04331683A1
    公开(公告)日:1982-05-25
    The compounds of the invention are certain new propenamides and 2-butenamides having a (carboxyalkanamido)phenyl or a (carboxyalkenamido)phenyl group at the 3-position, and certain esters thereof, and certain cyclopropanecarboxamide compounds having a (carboxyalkanamido)phenyl group or a (carboxyalkenamido)phenyl group at the 2-position, and certain esters thereof. The compounds are useful for antagonizing the spasmogenic activity of slow-reacting substance of anaphylaxis (SRS-A) in a human subject. In particular, the compounds of the invention are useful for preventing and treating certain obstructive airways diseases, notably allergic bronchial asthma, allergic rhinitis and certain skin disorders, in human subjects.
    本发明的化合物是一些新的丙烯酰胺和2-丁烯酰胺,在3位具有(羧基烷酰胺)苯基或(羧基烯酰胺)苯基,以及某些酯类化合物和在2位具有(羧基烷酰胺)苯基或(羧基烯酰胺)苯基的某些环丙烷羧酰胺化合物,以及某些酯类化合物。这些化合物对于拮抗人体内慢反应过敏物质(SRS-A)的痉挛原性活性非常有用。特别地,本发明的化合物对于预防和治疗某些阻塞性呼吸道疾病,尤其是过敏性支气管哮喘、过敏性鼻炎和某些皮肤疾病在人体内非常有用。
  • Stereoselective <i>N</i>-Heterocyclic-Carbene-Catalyzed Formal [4 + 2] Cycloaddition: Access to Chiral Heterocyclic Cyclohexenones
    作者:Ladislav Lóška、Vojtěch Dočekal、Ivana Císařová、Jan Veselý
    DOI:10.1021/acs.orglett.2c04021
    日期:2023.1.13
    alkenes containing a polarized double bond with an azolium-dienolate intermediate generated from α-bromo-α,β-unsaturated aldehydes without external oxidation of the Breslow intermediate. Heterocyclic cyclohexenones were produced in good isolated yields (typically about 90%) with good stereochemical outcomes (in most cases, dr > 20/1, and ee = 70–99%). The synthetic utility of the protocol was exemplified
    本研究报告了一种不对称 NHC 催化的杂环烯烃的正式 [4 + 2] 环加成反应,该杂环烯烃含有极化双键和由 α-溴-α,β-不饱和醛生成的唑鎓-二烯醇中间体,无需 Breslow 中间体的外部氧化。杂环环己烯酮以良好的分离产率(通常约为 90%)和良好的立体化学结果(在大多数情况下,dr > 20/1,并且 ee = 70-99%)产生。该协议的综合效用以杂环烯烃的范围为例。
查看更多